Last update May 20, 2024

C8 H7 ClN2 O2 S

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

A drug with hyperglycemic and antihypertensive action via peripheral vasodilatation. Indicated orally (2 to 3 daily doses) in the treatment of unresponsive hyperglycemia by hyperinsulinism and intravenously in hypertensive crises. Its use is authorized in the neonatal and infant period.

It is excreted in breast milk in small amounts, but could be clinically significant. (Saito 2022)

A newborn partially breastfed by a mother taking diazoxide orally had no clinical problems or alterations in blood glucose at one month of life. (Saito 2022)

If Diazoxide is taken during lactation, it is advisable to monitor the infant's blood glucose regularly.

Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable (Schaefer 2015 p790), especially during the neonatal period and in case of prematurity.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

C8 H7 ClN2 O2 S is Diazoxide in Molecular formula.

Is written in other languages:

Pharmacokinetics

Variable Value Unit
Molecular weight 231 daltons
Protein Binding 90 %
pKa 8.74 -
Tmax 0.1 hours
28 ± 8.3 hours
Theoretical Dose 0.11 - 0.46 mg/Kg/d
Relative Dose 3.6 - 15.9 %

References

  1. Saito J, Kawasaki H, Adachi N, Sasaki A, Yakuwa N, Suzuki T, Sago H, Yamatani A, Horikawa R, Murashima A. Diazoxide during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum: a case report. Gynecol Endocrinol. 2022 Jun;38(6):528-530. Abstract
  2. Pfizer. Diazoxide (injection). Drug Summary. 2017 Full text (in our servers)
  3. Merck. Diazoxide (oral). Drug Summary. 2015 Full text (in our servers)
  4. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation. Treatment options and risk assessment. Elsevier, Third Edition. 2015

Total visits

1,379

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM